Cargando…
Neutrophils dominate the immune cell composition in non-small cell lung cancer
The response rate to immune checkpoint inhibitor therapy for non-small-cell lung cancer (NSCLC) is just 20%. To improve this figure, several early phase clinical trials combining novel immunotherapeutics with immune checkpoint blockade have been initiated. Unfortunately, these trials have been desig...
Autores principales: | Kargl, Julia, Busch, Stephanie E., Yang, Grace H. Y., Kim, Kyoung-Hee, Hanke, Mark L., Metz, Heather E., Hubbard, Jesse J., Lee, Sylvia M., Madtes, David K., McIntosh, Martin W., Houghton, A. McGarry |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5296654/ https://www.ncbi.nlm.nih.gov/pubmed/28146145 http://dx.doi.org/10.1038/ncomms14381 |
Ejemplares similares
-
Annexin A2/TLR2/MYD88 pathway induces arginase 1 expression in tumor-associated neutrophils
por: Zhang, Huajia, et al.
Publicado: (2022) -
Identification of Novel Low-Density Neutrophil Markers Through Unbiased High-Dimensional Flow Cytometry Screening in Non-Small Cell Lung Cancer Patients
por: Valadez-Cosmes, Paulina, et al.
Publicado: (2021) -
Neutrophil Elastase-Mediated Degradation of IRS-1 Accelerates Lung Tumor Growth
por: Houghton, A. McGarry, et al.
Publicado: (2010) -
Diffuse large B-cell lymphoma (DLBCL) is infiltrated with activated CD8(+) T-cells despite immune checkpoint signaling
por: Greenbaum, Adam M., et al.
Publicado: (2022) -
A case series of morbid COPD exacerbations during immune checkpoint inhibitor therapy in cancer patients
por: Nair, Viswam S., et al.
Publicado: (2021)